About the Company
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
Employees
10
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CTXR News
Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts
Citius Pharmaceuticals, Inc. (CTXR) announced the FDA has accepted the resubmission of the Biologics License Application for LYMPHIR, ...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
NOTE: This content is not written by or endorsed by "KOIN", its advertisers, or Nexstar Media Inc.
Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials
Citius Pharmaceuticals Inc (NASDAQ:CTXR) reported a decrease in R&D expenses, reflecting the completion of certain clinical trials, but saw an increase in G&A expenses due to pre-launch activities.
Citius Pharmaceuticals Inc (CTXR)
Investing.com - Citius Pharma (NASDAQ: CTXR) reported third quarter EPS of $-0.060, in line with the analyst estimate of $-0.060. Revenue for the quarter came in at $0.00 versus... Citius Pharma ...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
About Citius Pharmaceuticals, Inc. Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company ...
Citius Pharmaceuticals Inc CTXR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
Likewise, our upcoming end of Phase 2 meeting with the FDA should provide valuable input on the development plan for Halo-Lido," stated Leonard Mazur, Chairman and CEO of Citius. "Importantly, we ...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIRâ„¢ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma ...
Loading the latest forecasts...